All News
Lipids and Inflammation in Rheumatoid Arthritis
In the realm of chronic inflammation, lipid abnormalities are well-recognized as pivotal contributors to the progression and clinical manifestations of atherosclerosis.
Read ArticleDepends on Where You’re Looking (8.9.2024)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week.
Read ArticleLocation, Location, Location (7.26.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Location matters; Geo-rheumatology?
Read ArticlePEXIVAS: Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis Patients
A secondary analysis of the PEXIVAS study showed antineutrophil cytoplasmic antibody–associated vasculitis (AAV) patients complicated by diffuse alveolar hemorrhage (DAH) may have improved with plasma exchange and glucocorticoids, the results did not achieve significance.
Read ArticleBest Rheumatologists (7.19.2024)
This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.
Read ArticleUpdated EULAR Recommendations on the Treatment of Systemic Sclerosis
Medscape has published an overview to the 2024 updated recommendations for the treatment of systemic sclerosis (SSc) presented in Vienna at EULAR 2024 by Professor Francesco Del Galdo, MD, PhD on behalf of a 27 member task force.
Read ArticlePathogenesis of Autoimmune Liver Disease
Autoimmune liver diseases (ALDs), including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), are complex conditions involving the liver's immune-mediated damage.
Read ArticlePNAS & Nature Insights into Lupus Pathogenesis
Two prominent medical journals this week published new insights into the pathogenesis of systemic lupus erythematosus (SLE), with both inidicating promient roles for T cells in what is a classically viewed as a humoral (B cell) disorder.
Read ArticleProgress in SLE with new mRNA CAR-T cell Trial
Cartesian Therapeutics, has announced their first-in-class mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) therapy has been given to the first systematic lupus erythematosus (SLE). patient in a Phase 2 open-label clinical trial.
Read Article
Links:
Links:
Links:
Links:


